These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 2677242

  • 1. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
    Da Prada M, Kettler R, Keller HH, Burkard WP, Haefely WE.
    J Neural Transm Suppl; 1989; 28():5-20. PubMed ID: 2677242
    [Abstract] [Full Text] [Related]

  • 2. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
    Da Prada M, Keller HH, Kettler R.
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
    [Abstract] [Full Text] [Related]

  • 3. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration.
    Urichuk LJ, Allison K, Holt A, Greenshaw AJ, Baker GB.
    J Affect Disord; 2000 May; 58(2):135-44. PubMed ID: 10781703
    [Abstract] [Full Text] [Related]

  • 4. [Hypertensive crises with reversible inhibitors of monoamine oxidases? Results of tyramine interaction studies].
    Bieck PR.
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():25-31. PubMed ID: 2587674
    [Abstract] [Full Text] [Related]

  • 5. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
    Lavian G, Finberg JP, Youdim MB.
    Clin Neuropharmacol; 1993 Aug; 16 Suppl 2():S1-7. PubMed ID: 8313392
    [Abstract] [Full Text] [Related]

  • 6. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats.
    Kettler R, Da Prada M, Burkard WP.
    Acta Psychiatr Scand Suppl; 1990 Aug; 360():101-2. PubMed ID: 2248058
    [Abstract] [Full Text] [Related]

  • 7. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE.
    J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611
    [Abstract] [Full Text] [Related]

  • 8. The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors.
    Alemany R, Olmos G, García-Sevilla JA.
    Br J Pharmacol; 1995 Feb; 114(4):837-45. PubMed ID: 7773544
    [Abstract] [Full Text] [Related]

  • 9. Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine.
    Waldmeier PC.
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Mar; 17(2):183-98. PubMed ID: 8430214
    [Abstract] [Full Text] [Related]

  • 10. Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide.
    Waldmeier PC, Stöcklin K.
    Eur J Pharmacol; 1990 May 16; 180(2-3):297-304. PubMed ID: 2365007
    [Abstract] [Full Text] [Related]

  • 11. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.
    Bieck PR, Antonin KH.
    J Neural Transm Suppl; 1989 May 16; 28():21-31. PubMed ID: 2794993
    [Abstract] [Full Text] [Related]

  • 12. Some basic aspects of reversible inhibitors of monoamine oxidase-A.
    Da Prada M, Kettler R, Burkard WP, Lorez HP, Haefely W.
    Acta Psychiatr Scand Suppl; 1990 May 16; 360():7-12. PubMed ID: 2248079
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The lack of hepatotoxicity in the rat with the new and reversible MAO-A inhibitor moclobemide in contrast to iproniazid.
    Schläppi B.
    Arzneimittelforschung; 1985 May 16; 35(5):800-3. PubMed ID: 4026902
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo.
    Colzi A, D'Agostini F, Cesura AM, Borroni E, Da Prada M.
    J Pharmacol Exp Ther; 1993 Apr 16; 265(1):103-11. PubMed ID: 8473998
    [Abstract] [Full Text] [Related]

  • 17. Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491.
    Keller HH, Kettler R, Keller G, Da Prada M.
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Jan 16; 335(1):12-20. PubMed ID: 3574489
    [Abstract] [Full Text] [Related]

  • 18. Pre-clinical pharmacology of moclobemide. A review of published studies.
    Burkard WP, Da Prada M, Keller HH, Kettler R, Haefely W.
    Br J Psychiatry Suppl; 1989 Oct 16; (6):84-8. PubMed ID: 2695131
    [Abstract] [Full Text] [Related]

  • 19. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression.
    Lotufo-Neto F, Trivedi M, Thase ME.
    Neuropsychopharmacology; 1999 Mar 16; 20(3):226-47. PubMed ID: 10063483
    [Abstract] [Full Text] [Related]

  • 20. Enhancement of 5-HT-induced anorexia: a test of the reversibility of monoamine oxidase inhibitors.
    Fletcher PJ, Yu PH.
    Psychopharmacology (Berl); 1989 Mar 16; 98(2):265-8. PubMed ID: 2502797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.